Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population.

Ziteng WangEleanor Jing Yi CheongPipin KojodjojoEric Chun Yong Chan

Published in: Cardiovascular drugs and therapy (2021)

Close monitoring of bleeding tendency is essential for elderly patients with moderate renal impairment receiving co-prescribed rivaroxaban and amiodarone. Further dose reduction is recommended for rivaroxaban to mitigate this specific DDDI risk.

Keyphrases

atrial fibrillation
venous thromboembolism
pulmonary embolism
middle aged
high intensity
community dwelling